

Robert K Hills

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7260186/robert-k-hills-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

175
papers

13,367
citations

53
h-index

115
g-index

180
ext. papers

15,294
ext. citations

5
avg, IF

5.97
L-index

#	Paper	IF	Citations
175	Gemtuzumab ozogamicin in (KMT2A)-rearranged adult acute myeloid leukaemia (AML) in the UK Medical Research Council AML15 and AML16 trials. <i>British Journal of Haematology</i> , 2021 ,	4.5	
174	Historical controls and venous thromboembolism prophylaxis in acute lymphoblastic leukaemia: things can only get better?. <i>British Journal of Haematology</i> , 2021 ,	4.5	
173	Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses. <i>Journal of Clinical Oncology</i> , 2021 , 39, 890-901	2.2	7
172	Diagnosing Diamond-Blackfan anaemia: 'Vorsprung durch Technik'. <i>British Journal of Haematology</i> , 2021 , 193, 1030-1031	4.5	
171	A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial. <i>British Journal of Haematology</i> , 2021 , 194, 298-308	4.5	1
170	Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study. <i>British Journal of Haematology</i> , 2021 , 192, 832-842	4.5	4
169	Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemia. <i>Leukemia Research</i> , 2021 , 108, 106553	2.7	
168	Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020 , 191, 231-242	4.5	1
167	The clinical impact of mutant DNMT3A R882 variant allele frequency in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020 , 189, e81-e86	4.5	2
166	Increased frequency of CD4 PD-1 HLA-DR T cells is associated with disease progression in CLL. <i>British Journal of Haematology</i> , 2020 , 188, 872-880	4.5	13
165	Twenty five years of UK trials in acute myeloid leukaemia: what have we learned?. <i>British Journal of Haematology</i> , 2020 , 188, 86-100	4.5	9
164	Evaluating sixty years of UK trials research in acute myeloid leukaemia: lessons for trial design, past, present and future. <i>British Journal of Haematology</i> , 2020 , 188, 29-35	4.5	2
163	Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. <i>Haematologica</i> , 2020 , 105, 161-169	6.6	8
162	Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020 , 188, 852-859	4.5	9
161	Molecular MRD status and outcome after transplantation in NPM1-mutated AML. <i>Blood</i> , 2020 , 135, 680-688		58
160	Telomere length predicts for outcome to FCR chemotherapy in CLL. <i>Leukemia</i> , 2019 , 33, 1953-1963	10.7	10
159	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019 , 393, 1440-1452	40	137

158	Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. <i>Blood</i> , 2019 , 133, 1140-1151	2.2	61
157	Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adults. <i>British Journal of Haematology</i> , 2019 , 186, 130-133	4.5	5
156	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. <i>Blood</i> , 2018 , 131, 1275-1291	2.2	528
155	Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018 , 59, 493-496	1.9	5
154	Variable outcome and methylation status according to mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatment. <i>Haematologica</i> , 2018 , 103, 91-100	6.6	5
153	High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2018 , 8, 68	7	23
152	Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial. <i>Haematologica</i> , 2018 , 103, 1654-1661	6.6	8
151	Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial. <i>Blood</i> , 2018 , 132, 1452-1454	2.2	31
150	Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1486-1497	2.2	94
149	Comparison of Cure Rates between Gemtuzumab Ozogamicin Plus Standard of Care Chemotherapy Vs Standard of Care Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2018 , 132, 2712-2712	2.2	2
148	Pre-Transplant NPM1 Mutant Transcript Level Is Highly Predictive of Outcome after Allograft and Thresholds Are Dependent on FLT3 ITD Status. <i>Blood</i> , 2018 , 132, 2739-2739	2.2	1
147	The Achievement of Complete Remission Is Associated with Improved Quality of Life in Non-Intensively Treated Patients with Acute Myeloid Leukemia: Results of the UK NCRI LI-1 Trial. <i>Blood</i> , 2018 , 132, 372-372	2.2	1
146	Outcomes in Relapsed/Refractory Patients with FLT3-ITD Mutated AML Are Poor When Treated with Non-Targeted Therapy with a Potential Role for Stem Cell Transplantation: Results from the NCRI AML Trials. <i>Blood</i> , 2018 , 132, 1392-1392	2.2	2
145	Telomere Length Predicts for Outcome to FCR Chemoimmunotherapy in CLL. <i>Blood</i> , 2018 , 132, 1854-1854	2.2	2
144	Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice. <i>Blood</i> , 2018 , 131, 636-648	2.2	23
143	No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials. <i>Blood</i> , 2018 , 131, 468-471	2.2	29
142	CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML. <i>Blood Advances</i> , 2018 , 2, 964-968	7.8	12
141	Will Rogers: actor, humourist and ALL epidemiologist?. <i>British Journal of Haematology</i> , 2018 , 182, 755	4.5	2

140	A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. <i>Blood</i> , 2017 , 129, 1143-1154	2.2	99
139	Non-inferiority trials: No better? No worse? No change? No pain?. <i>British Journal of Haematology</i> , 2017 , 176, 883-887	4.5	3
138	Structural and functional analysis of the human POT1-TPP1 telomeric complex. <i>Nature Communications</i> , 2017 , 8, 14928	17.4	58
137	Telomere length is an independent prognostic marker in MDS but not in de novo AML. <i>British Journal of Haematology</i> , 2017 , 178, 240-249	4.5	16
136	Telomere length is a critical determinant for survival in multiple myeloma. <i>British Journal of Haematology</i> , 2017 , 178, 94-98	4.5	21
135	Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	108
134	MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 154-154	2.2	
133	Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m ² with 6 mg/m ² in the NCRI AML17 Trial. <i>Haematologica</i> , 2016 , 101, 724-31	6.6	46
132	An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation. <i>Haematologica</i> , 2016 , 101, 1351-1358	6.6	51
131	Assessment of Minimal Residual Disease in Standard-Risk AML. <i>New England Journal of Medicine</i> , 2016 , 374, 422-33	59.2	500
130	Axl/ Mer Inhibitor ONO-9330547 As a Novel Therapeutic Agent in a Stromal Co-Culture Model of Primary Acute Myeloid Leukaemia (AML). <i>Blood</i> , 2016 , 128, 2754-2754	2.2	3
129	Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2016 , 11, e0163291	3.7	7
128	The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias. <i>Oncotarget</i> , 2016 , 7, 16650-62	3.3	8
127	Mitochondrial profiling as a predictive biomarker for response to cytarabine-based treatment of acute myelogenous leukemia.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7017-7017	2.2	
126	KIR gene haplotype: an independent predictor of clinical outcome in MDS patients. <i>Blood</i> , 2016 , 128, 2819-2823	2.2	19
125	Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI. <i>Haematologica</i> , 2016 , 101, e284-6	6.6	15
124	Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia. <i>Blood</i> , 2016 , 128, 449-52	2.2	39
123	Assessment of Minimal Residual Disease in Standard-Risk AML. <i>New England Journal of Medicine</i> , 2016 , 375, e9	59.2	24

122	The value of molecular stratification for CEBPA(DM) and NPM1(MUT) FLT3(WT) genotypes in older patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2016 , 172, 573-80	4.5	14
121	Assessing the prognostic value of preoperative carcinoembryonic antigen-specific T-cell responses in colorectal cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	12
120	Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. <i>Blood</i> , 2015 , 125, 2985-94	2.2	39
119	Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. <i>Lancet Neurology</i> , 2015 , 14, 1171-81	24.1	101
118	Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2015 , 16, 1295-303	31.7	316
117	Disease evolution and outcomes in familial AML with germline CEBPA mutations. <i>Blood</i> , 2015 , 126, 1214-23	2.2	104
116	Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. <i>Blood</i> , 2015 , 125, 2923-32	2.2	43
115	An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 low blasts. <i>British Journal of Haematology</i> , 2015 , 170, 80-4	4.5	10
114	Cord Blood-Derived Quiescent CD34+ Cells Are More Transcriptionally Matched to AML Blasts Than Cytokine-Induced Normal Human Hematopoietic CD34+ Cells. <i>Gene Expression</i> , 2015 , 16, 169-175	3.4	
113	A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. <i>Blood</i> , 2015 , 125, 3878-85	2.2	176
112	Simpson's Paradox and the Impact of Different DNMT3A Mutations on Outcome in Younger Adults With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2072-83	2.2	59
111	HFE Gene Mutation Status Predicts Response to Gemtuzumab Ozogamicin in AML. <i>Blood</i> , 2015 , 126, 1307-1307	2.2	7
110	Quizartinib Significantly Improves Overall Survival in FLT3-ITD Positive AML Patients Relapsed after Stem Cell Transplantation or after Failure of Salvage Chemotherapy: A Comparison with Historical AML Database (UK NCRI data). <i>Blood</i> , 2015 , 126, 2557-2557	2.2	8
109	PP2A Inhibition By CIP2A or SETBP1 Leads to Elevated Levels of AKT S473 Which Can be Used As a Biomarker of Outcome in Acute Myeloid Leukaemia. <i>Blood</i> , 2015 , 126, 1396-1396	2.2	
108	A Comparison of 1 or 2 Courses of High Dose Cytarabine As Consolidation in Younger Patients with AML: First Results of the UK NCRI AML17 Trial. <i>Blood</i> , 2015 , 126, 221-221	2.2	1
107	Who is an "older" patient with acute myeloid leukaemia (AML)? An investigation of two NCRI/AML trials. <i>British Journal of Haematology</i> , 2014 , 165, 147-51	4.5	4
106	Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. <i>Lancet Oncology</i> , 2014 , 15, 986-96	21.7	410
105	The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon treatment. <i>Gut</i> , 2014 , 63, 515-24	19.2	44

104	International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1919-26	2.2	126
103	The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts. <i>Haematologica</i> , 2014 , 99, 858-64	6.6	35
102	Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. <i>Blood</i> , 2014 , 124, 273-6	2.2	87
101	Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. <i>British Journal of Haematology</i> , 2014 , 167, 214-23	4.5	67
100	ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1326-31 ^{1.9}		12
99	Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?. <i>Best Practice and Research in Clinical Haematology</i> , 2014 , 27, 53-61	4.2	23
98	A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m2 and 6mg/m2 Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial. <i>Blood</i> , 2014 , 124, 2308-2308	2.2	2
97	Molecular Detection of Minimal Residual Disease Provides the Most Powerful Independent Prognostic Factor Irrespective of Clonal Architecture in Nucleophosmin (NPM1) Mutant Acute Myeloid Leukemia. <i>Blood</i> , 2014 , 124, 70-70	2.2	3
96	A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia. <i>Blood</i> , 2014 , 124, 3747-3747		22
95	Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3360-8	2.2	247
94	Does BCR/ABL1 positive acute myeloid leukaemia exist?. <i>British Journal of Haematology</i> , 2013 , 161, 541-50	4.5	55
93	GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations. <i>British Journal of Haematology</i> , 2013 , 161, 701-5	4.5	39
92	Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. <i>Blood</i> , 2013 , 121, 2424-31	2.2	75
91	Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling. <i>Blood</i> , 2013 , 122, 3322-30	2.2	134
90	Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2013 , 160, 188-98	4.5	35
89	Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. <i>Blood</i> , 2013 , 122, 1384-94	2.2	109
88	Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4123-31	2.2	216
87	Reply to D. Przepioraka et al and M.K. Jensen. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1700-1; discussion 1701	2.2	

86	Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy. <i>British Journal of Haematology</i> , 2013 , 160, 861-3	4.5	5
85	Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1293-301	2.2	148
84	The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials. <i>Blood</i> , 2013 , 122, 356-356	2.2	8
83	Reasons For Survival Improvement In Core Binding Factor AML: A 25 Year Analysis Of The UK MRC/NCRI AML Trials. <i>Blood</i> , 2013 , 122, 358-358	2.2	7
82	The ATRA Question In AML: Lack Of Benefit Overall Or In Any Molecular Subgroup In The NCRI AML16 Trial. <i>Blood</i> , 2013 , 122, 493-493	2.2	3
81	AC220 (Quizartinib) Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukaemia: Experience From The AML18 Pilot Trial. <i>Blood</i> , 2013 , 122, 622-622	2.2	18
80	Prediction Of Therapeutic Resistance In Adult Acute Myeloid Leukemia: Analysis Of 4,550 Newly Diagnosed Patients From MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center. <i>Blood</i> , 2013 , 122, 64-64	2.2	1
79	The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. <i>British Journal of Haematology</i> , 2012 , 158, 519-22	4.5	48
78	A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia. <i>Blood</i> , 2012 , 119, 196-205	2.2	23
77	Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. <i>Blood</i> , 2012 , 120, 2826-35	2.2	293
76	The contribution of randomized trials to the cure of haematological disorders from Bradford Hill onwards. <i>British Journal of Haematology</i> , 2012 , 158, 691-9	4.5	4
75	Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3924-31	2.2	305
74	Defining the prognosis of early stage chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2012 , 156, 499-507	4.5	38
73	Prognostic Significance of the French-American-British (FAB) Morphologic Subclassification of Acute Myeloid Leukemia, Not Otherwise Specified In the 2008 WHO Classification: Analysis of 5,848 Newly Diagnosed Patients From HOVON, MRC/NCRI, SWOG, and MD Anderson Cancer Center. <i>Blood</i> , 2012 , 120, 510-510	2.2	
72	Reduced Intensity Transplant May Improve Survival in Patients Over the Age of 40, Especially If a Sibling Donor Is Used: Pooled Analysis of 2454 Patients and 407 Transplants in the UK NCRI AML15 and AML16 Trials. <i>Blood</i> , 2012 , 120, 231-231	2.2	
71	The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. <i>Blood</i> , 2011 , 118, 409-12	2.2	200
70	Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. <i>Blood</i> , 2011 , 117, 4726-35	2.2	247
69	Applicability of a "Pick a Winner" trial design to acute myeloid leukemia. <i>Blood</i> , 2011 , 118, 2389-94	2.2	61

68	Who should be transplanted in first remission of acute myeloid leukaemia?. <i>Current Treatment Options in Oncology</i> , 2011 , 12, 329-40	5.4	3
67	Independent prognostic variables in acute myeloid leukaemia. <i>Blood Reviews</i> , 2011 , 25, 39-51	11.1	80
66	CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. <i>Leukemia Research</i> , 2011 , 35, 750-6	2.7	53
65	Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 369-77	2.2	485
64	The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial. <i>Blood</i> , 2011 , 118, 582-582	2.2	7
63	Quantitation of Leukemic Stem Cell Populations Predicts Clinical Outcome in Acute Myeloid Leukaemia. <i>Blood</i> , 2011 , 118, 638-638	2.2	1
62	Single Nucleotide Polymorphism Array (SNP-A) Karyotype Is the Best Predictor of Prognosis In Normal Cytogenetics Acute Myeloid Leukaemia (AML). <i>Blood</i> , 2011 , 118, 411-411	2.2	
61	Mutations in a Large Cohort of Young Adult Patients with Core Binding Factor Acute Myeloid Leukemia: Impact on Outcome and the Selection of Patients for Alternative Treatment Including Transplantation in First Complete Remission. <i>Blood</i> , 2011 , 118, 419-419	2.2	
60	European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2389-95	2.2	138
59	Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. <i>Journal of Clinical Oncology</i> , 2010 , 28, 586-95	2.2	174
58	Reply to S. Nagai et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e63-e64	2.2	
57	Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2674-81	2.2	217
56	Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. <i>Blood</i> , 2010 , 116, 354-65	2.2	1353
55	Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2739-47	2.2	216
54	The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. <i>Blood</i> , 2010 , 115, 948-56	2.2	90
53	The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. <i>Blood</i> , 2010 , 116, 2779-82	2.2	105
52	PERineal Assessment and Repair Longitudinal Study (PEARLS): protocol for a matched pair cluster trial. <i>BMC Pregnancy and Childbirth</i> , 2010 , 10, 10	3.2	25
51	Younger Adult Acute Myeloid Leukemia (AML) Patients with IDH2-R140 Mutations Have a Significantly Better Prognosis Than Those with Either IDH2-R172 or IDH1 Mutations. <i>Blood</i> , 2010 , 116, 100-100	2.2	1

50	The Addition of Gemtuzumab Ozogamicin to Low Dose Ara-C Improves Remission Rates but Not Survival: Results of the UK LRF AML14 and NCRI AML16 Pick a Winner Comparison. <i>Blood</i> , 2010 , 116, 18-18	2.2	4
49	A Phase Ib Study Combining the mTOR Inhibitor Everolimus (RAD001) with Low-Dose Cytarabine In Untreated Elderly AML. <i>Blood</i> , 2010 , 116, 3299-3299	2.2	5
48	Prognostic Significance of Cryptic Genomic Aberrations In AML with Normal Karyotype. <i>Blood</i> , 2010 , 116, 2729-2729	2.2	
47	Detection of Immunophenotypic Residual Disease After Induction Therapy Is An Independent Prognostic Factor for Duration of Remission In Older AML Patients Treated Intensively. <i>Blood</i> , 2010 , 116, 2714-2714	2.2	
46	A Polymorphism In the 3'UTR Region of ABCB1 Is Associated with Increased Allele Activity with Corresponding Increases In P-Glycoprotein Expression and Function. <i>Blood</i> , 2010 , 116, 3990-3990	2.2	1
45	A Distinct Signature of Natural Killer Cell KIR Gene Frequencies In Secondary AML Compared with De Novo AML and Normal Controls. <i>Blood</i> , 2010 , 116, 1697-1697	2.2	
44	A Functional Polymorphism In the CD95 Cell Death Receptor Associated with Prognosis In Acute Promyelocytic Leukemia. <i>Blood</i> , 2010 , 116, 756-756	2.2	
43	Analysis of the Interaction of Induction Regimens with P-Glycoprotein Expression In Patients with Acute Myeloid Leukaemia: Results From the MRC AML15 Trial. <i>Blood</i> , 2010 , 116, 2724-2724	2.2	
42	Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2009 , 27, 763-9	2.2	45
41	Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3650-8 ²	2.2	279
40	Independent prognostic factors for AML outcome. <i>Hematology American Society of Hematology Education Program</i> , 2009 , 385-95	3.1	120
39	Laparoscopic uterosacral nerve ablation for alleviating chronic pelvic pain: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 302, 955-61	27.4	84
38	Balancing treatment allocations by clinician or center in randomized trials allows unacceptable levels of treatment prediction. <i>Journal of Evidence-Based Medicine</i> , 2009 , 2, 196-204	6.1	14
37	The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. <i>British Journal of Haematology</i> , 2009 , 145, 318-32	4.5	122
36	Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5195-201	2.2	337
35	Attempts to Optimise Induction and Consolidation Chemotherapy in Patients with Acute Myeloid Leukaemia: Results of the MRC AML15 Trial.. <i>Blood</i> , 2009 , 114, 484-484	2.2	8
34	Outcome of Reduced Intensity Allografts in Patients Aged Over 45 Years with Acute Myeloid Leukaemia: Initial Results of the MRC AML15 Trial.. <i>Blood</i> , 2009 , 114, 523-523	2.2	1
33	Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5429-35	2.2	167

32	The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. <i>Blood</i> , 2008 , 111, 2776-84	2.2	555
31	Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease. <i>Blood</i> , 2008 , 112, 444-5; author reply 445	2.2	29
30	A Retrospective Comparison of Matched Elderly Patients Treated with Laromustine (Clometazine) or Best Supportive Care or Low Dose Ara-C in the LRF AML14 Trial. <i>Blood</i> , 2008 , 112, 2960-2960	2.2	1
29	Low Dose Ara-C Versus Low Dose Ara-C and Tipifarnib: Result of the UK NCRI AML16 Picky a Winner Comparison. <i>Blood</i> , 2008 , 112, 2962-2962	2.2	3
28	The Impact of FLT3-ITD and NPM1 Mutational Status on the Outcome of ATRA Therapy in Patients with Non-APL AML: Results of the UK MRC AML12 Trial. <i>Blood</i> , 2008 , 112, 554-554	2.2	3
27	Predictive Value of Minimal Residual Disease (MRD) Monitoring by RQ-PCR in WT1 Positive Patients Entered in the UK MRC AML-15 Trial. <i>Blood</i> , 2008 , 112, 697-697	2.2	2
26	The Impact of MN1 Over-Expression on the Outcome of Younger Patients with AML Treated with Intensive Chemotherapy with or without ATRA Therapy. <i>Blood</i> , 2008 , 112, 2978-2978	2.2	1
25	CSL-TREX: A Novel Alternatively Spliced Isoform of CSL (RBPJ-K) Predominates Over the Full-Length Isoform in Many Patients with Acute Myeloid Leukaemia, Can Activate Notch Signalling and Is Associated with Improved Outcome.. <i>Blood</i> , 2008 , 112, 3364-3364	2.2	1
24	A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. <i>Cancer</i> , 2007 , 109, 1114-24	6.4	478
23	FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. <i>Blood</i> , 2007 , 110, 1262-70	2.2	239
22	Continuous versus interrupted sutures for repair of episiotomy or second degree tears. <i>Cochrane Database of Systematic Reviews</i> , 2007 , CD000947		50
21	Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. <i>Lancet</i> , 2007 , 370, 2020-9	40	1012
20	Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial.. <i>Blood</i> , 2007 , 110, 589-589	2.2	15
19	Mutation of the Wilms Tumor 1 Gene Is a Poor Prognostic Factor Associated with Chemoresistance in Normal Karyotype Acute Myeloid Leukemia.. <i>Blood</i> , 2007 , 110, 361-361	2.2	
18	Minimal Residual Disease Monitoring by RQ-PCR in Core Binding Factor Positive AML Allows Risk-Stratification and Predicts Relapse: Results of the UK MRC AML-15 Trial.. <i>Blood</i> , 2007 , 110, 543-543	2.2	
17	Assessing new interventions in women's health. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2006 , 20, 713-28	4.6	5
16	Problems with up-front randomization in clinical trials. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5471-2; author reply 5472-3	2.2	2
15	A randomised-controlled trial in England of a postnatal midwifery intervention on breast-feeding duration. <i>Midwifery</i> , 2006 , 22, 262-73	2.8	35

14	Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. <i>British Journal of Haematology</i> , 2006 , 132, 576-83	4.5	81
13	Designing clinical trials in women's health. <i>Reviews in Gynaecological and Perinatal Practice</i> , 2006 , 6, 33-39		1
12	The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy for AML Improves Disease Free Survival without Extra Toxicity: Preliminary Analysis of 1115 Patients in the MRC AML15 Trial.. <i>Blood</i> , 2006 , 108, 13-13	2.2	45
11	A Sensitive Risk Score for Directing Treatment in Younger Patients with AML.. <i>Blood</i> , 2006 , 108, 18-18	2.2	9
10	The Feasibility of Combining Daunorubicin, Clofarabine and Gemtuzumab Ozogamicin Is Feasible and Effective. A Pilot Study.. <i>Blood</i> , 2006 , 108, 1950-1950	2.2	4
9	Effectiveness of Clofarabine in Elderly AML Patients with Adverse Cytogenetics Unfit for Intensive Chemotherapy.. <i>Blood</i> , 2006 , 108, 1985-1985	2.2	2
8	A Phase II Study (BioV-121) of Clofarabine Monotherapy First Line in Patients Aged 65 Years or Older with Acute Myeloid Leukemia for Whom Standard Intensive Chemotherapy Is Not Considered Suitable.. <i>Blood</i> , 2006 , 108, 425-425	2.2	14
7	Long-term results of the MRC AML10 trial. <i>Clinical Advances in Hematology and Oncology</i> , 2006 , 4, 445-516		15
6	No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. <i>Blood</i> , 2005 , 106, 3658-65	2.2	196
5	Measurement of beliefs about effectiveness of laparoscopic uterosacral nerve ablation. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2005 , 112, 243-6	3.7	7
4	Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. <i>Blood</i> , 2005 , 106, 3768-76	2.2	180
3	Prognostic Factors in Older AML Patients Receiving Intensive and Non-Intensive Therapy: Analysis of the UK AML11 and AML14 Trials.. <i>Blood</i> , 2005 , 106, 674-674	2.2	3
2	Continuous versus interrupted perineal repair with standard or rapidly absorbed sutures after spontaneous vaginal birth: a randomised controlled trial. <i>Lancet, The</i> , 2002 , 359, 2217-23	4.0	112
1	Research in cancer80-95		